In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report). The company’s ...

Sangamo (SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate ST-920 in the treatment of Fabry disease. Read more here.

Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: February 4 at 6:55:05 PM EST Loading Chart for MYGN ...

After hours: February 4 at 6:46:43 PM EST Loading Chart for NTLA ...

After hours: 7:35:55 p.m. EST ...